Stem Cell Banking Market to Surpass US$ 7.7 Billion by 2025, At a CAGR of 18.9% | Generated Opportunities for  Market Growth

The Global Stem Cell Banking Market, by Source Type (Cord Tissue and Cord Blood), by Service Type (Storage, Collection & Transportation, Analysis, and Processing), by Application (Thalassemia, Leukemia, Cerebral Palsy, Lymphoma, and Diabetes), and by Region (North America, Asia Pacific, Latin America, Europe, the Middle East, and Africa) had a market valuation of US$ 1,634.7 million in 2016 and is anticipated to grow at a CAGR of 18.9 percent during the forecast period (2017–2025).

Request for Analysis of COVID-19 Impact on Stem Cell Banking Market –
https://www.coherentmarketinsights.com/insight/request-sample/1354

Drivers

As consumer awareness over the use of umbilical cord blood and umbilical cord tissue stem cells in treatment increases, as well as the increasing application of cells in the treatment of diseases such as autism, lymphoma, anemia, etc., it is expected that the global stem cell banking market will gain a huge boost.

Improving the survival rate of patients after stem cell transplantation is expected to promote the growth of the global stem cell banking market. The increased use and application of stem cells in treating blood-related cancer patients is an important factor driving stem cell growth of the global stem cell banking market. According to data from the Leukemia and Lymphoma Association, in 2017, an estimated 172,910 people in the U.S. were diagnosed with leukemia, lymphoma, or myeloma in 2017, so stem cells are increasingly being used for effective treatment.

According to a 2013 study in the Journal of Clinical Oncology, stem cell transplantation for elderly blood cancer patients is safe and effective, and shows better results, and post-transplant complications (such as graft-versus-host disease) are reduced by 37%. The study also showed that the survival probability after one year of stem cell transplantation is about 42%, and the overall survival rate is also estimated to be 55%. In addition, the launch of innovative products and therapeutic therapies, such as the use of cord blood-derived hematopoietic stem cells for allogeneic therapy, is another factor driving market growth. In 2011, the FDA approved Hemacord, the first hematopoietic progenitor cell therapy (HPCC) approved by the New York Blood Center Company. Hemacord uses cord blood stem cells to treat certain hematopoietic diseases or blood formation. In addition, in 2014, Hemacord was awarded the best biotechnology product by Prix Galien USA.

Request PDF Brochure Report –
https://www.coherentmarketinsights.com/insight/request-pdf/1354

Manufacturers are focusing on regenerative medicine research to harness the potential of cord blood stem cells to treat diseases and conditions for which there is no known cure. The manufacturer is also working with academic researchers to help expand the potential uses of neonatal stem cell therapies, which may be available to patients and their families. In February 2018, the Institute of Integrative Biology collaborated with Anika Therapeutics, Inc. to develop an injectable mesenchymal stem cell (MSC) therapy for the treatment of osteoarthritis. In 2016, Axiogenesis AG and Metrion Biosciences Ltd. collaborated to validate, optimize and commercialize induced pluripotent stem cell-derived cells and tissues to accelerate drug discovery research. In addition, in 2015, MAG Pharmaceuticals, Inc. acquired Cord Blood Registry (CBR), a cord blood stem cell collection and storage company, for US$700 million to expand and diversify its maternal healthcare business.

Key Takeaways

Due to the increasing demand for personalized medicine in Asia Pacific, Europe, Latin America and the Middle East, and the benefits of low-risk immunotherapy, the global stem cell banking market is expected to grow at a CAGR of 18.9% during the forecast period.

Among the source types, the cord blood plate dominates the global stem cell bank market as cord blood stem cells have the ability to treat more than 80 blood-related diseases such as sickle cell anemia and thalassemia, as well as various types of leukemia and myeloma.

In applications, the lymphoma side dominates the global stem cell banking market on the back of the prevalence of these diseases continues to rise and the number of successful treatment procedures using stem cells to treat the disease has increased.

Reasons to Purchase this Report

Current and future of global Stem Cell Banking market outlook in the developed and emerging markets

The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.

Regions/countries that are expected to witness the fastest growth rates during the forecast period

The latest developments, market shares, and strategies that are employed by the major market players

Buy This Complete A Business Report With Flat US $2000 Off @
https://www.coherentmarketinsights.com/promo/buynow/1354

Table of Content

Global Stem Cell Banking Market Research Report

Section 1: Global Stem Cell Banking Industry Overview

Section 2: Global Economic Impact on Stem Cell Banking Industry

Section 3: Global Market Competition by Industry Producers

Section 4: Global Productions, Revenue (Value), according to Regions

Section 5: Global Supplies (Production), Consumption, Export, Import, geographically

Section 6: Global Productions, Revenue (Value), Price Trend, Product Type

Section 7: Global Market Analysis, on the basis of Application

Section 8: Stem Cell Banking Market Pricing Analysis

Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers

Inquire more about this report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1354

Key companies contributing in the global stem cell banking market include SciVision Biotech Inc., Merz Pharma GmbH & Co. KGaA., Integra LifeSciences Corporation, Galderma S.A., Allergan, Plc., Anika Therapeutics, Inc., Valeant Pharmaceuticals International, Inc., Suneva Medical, Sanofi S.A., and Sinclair Pharma Plc.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837